Navigation Links
VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
Date:3/20/2008

- Top Line Data Is Expected to Be Presented in Third Quarter -

SAN FRANCISCO, March 20 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed patient enrollment in its carotid endarterectomy (CEA) study, the first of three Phase 2 trials investigating VIA-2291, the company's lead product candidate.

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events associated with inflammation, including heart attack and stroke.

The CEA study enrolled 50 patients and is designed to provide direct evaluation of VIA-2291's effect on inflammation by analyzing plaque removed from the carotid arteries of patients treated with VIA-2291 or placebo. CEA is a surgical procedure to remove plaque from the carotid artery to increase blood flow to the brain in patients with significant blockage in the artery to reduce the risk of stroke. Patients who are diagnosed with carotid artery blockage are treated for three months with either VIA-2291 or placebo and then undergo a CEA procedure. The trial will also measure standard serum biomarkers of inflammation to measure reduction of inflammation in treated patients.

"Following analysis of the CEA study data, we expect to have important data with respect to VIA-2291's role in reducing vascular inflammation, as measured in the carotid plaque tissue," said Rebecca A. Taub, M.D., senior vice president of research and development of VIA Pharmaceuti
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  ResMed ... has signed a definitive agreement to acquire ... non-invasive ventilation and sleep-disordered breathing medical devices ... innovation and market reputation in China, combined with ResMed,s global leadership in sleep ... in China suffering ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... 2015  Unichem Pharmaceuticals ( USA ), ... tablets 25 mg 1000-count bottle to the consumer level. ... due to the identification of a Clopidogrel tablet found ... The risk associated with mistakenly taking a Clopidogrel tablet ... of experiencing Clopidogrel,s side effects which include bleeding and/or ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... BRISBANE, Australia, Oct. 3, 2011 Ventus Medical ... Sleep Apnea Therapy, an innovative, non-invasive treatment for ... Australia and New Zealand. BMedical Pty. Ltd. will ... in these countries. (Photo:   http://photos.prnewswire.com/prnh/20110209/SF45785-a ...
... Oct. 3, 2011 PAREXEL International Corporation (NASDAQ: ... of Fiscal Year 2012 on Monday, October 31, 2011 after ... available on PAREXEL,s website at www.PAREXEL.com and on ... PAREXEL will host a conference call and live webcast at ...
Cached Medicine Technology:Ventus Medical Launches Provent® Sleep Apnea Therapy in Australia and New Zealand 2Ventus Medical Launches Provent® Sleep Apnea Therapy in Australia and New Zealand 3PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call 2
(Date:7/30/2015)... ... July 30, 2015 , ... OSF Healthcare System has been ... Most Wired Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive ... by The Sisters of the Third Order of St. Francis . , Health ...
(Date:7/30/2015)... ... 2015 , ... Women's dating coach Simone Myers has just ... interested in improving their love lives using specific "lines" designed to trigger powerful ... public early this morning, has drawn praise from several dating and relationship advice ...
(Date:7/30/2015)... ... July 30, 2015 , ... Eyepartner is ... victims in San Diego, California’s Gaslamp Quarter Plaza for five years this September. ... actively monitor the area for any suspicious activity. These cameras are in place ...
(Date:7/30/2015)... ... , ... Google recently announced that it will be disclosing any incidents involving ... June 8, 2015 article published by Nasdaq , the powerful tech company maintains ... computer-driven cars, which such industry players as Tesla CEO Elon Musk believe may very ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care ... Angeles, and San Bernardino counties, today announced that Dr. Michael Demoratz, PhD, LCSW, ... Demoratz is a strong proponent of early access to palliative care services for ...
Breaking Medicine News(10 mins):Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3
... ... sector. , ... Alberta (PRWEB) March 5, 2010 -- ANT Wireless ("ANT" www.thisisant.com ), a division ... A noted leader in the design and manufacturing of sport precision instruments, ...
... ... of Nevada, a Las Vegas-based healthcare organization, announced the acquisition of Rainbow Medical Center, an ... Rainbow Medical Center is now part of the Fremont Medical Centers Division of HealthCare Partners ... (PRWEB) March ...
... ... leading cause of mortality in the U.S., according to the Centers for Disease Control ... Charleston, ... problem. The culprit…Hospital Acquired Infections (HAIs) and they have generated much attention over the ...
... Mt. Everest Summiter (with ... race across the Sahara desert this April 2010. Gary is doing this to raise awareness and ... ... miles (in sections approximate to 25, 34, 38, 82, 42, 22 km) run over 6 days ...
... during the 39th Annual Meeting of the American ... E. Washington Convention Center in Washington, DC, lead ... present a poster of a study titled "TLR2 ... Reactivation." Although oral co-infections (e.g. periodontal disease) are ...
... ... the safety of the company,s products are taken very seriously. , , ... Bloomingdale, IL (PRWEB) March 4, 2010 -- ... to lead healthier lives. Product safety and quality are the company,s highest priorities; therefore any ...
Cached Medicine News:Health News:Suunto Joins ANT+ Interoperable Ecosystem 2Health News:Suunto Joins ANT+ Interoperable Ecosystem 3Health News:HealthCare Partners of Nevada and Rainbow Medical Center Join Forces 2Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 2Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 3Health News:Mt. Everest Summiter Gary Guller (With One Arm) To Race Across Sahara in "The World's Toughest Stage Race" 2Health News:Mt. Everest Summiter Gary Guller (With One Arm) To Race Across Sahara in "The World's Toughest Stage Race" 3Health News:Periodontal pathogens enhance HIV-1 promoter activation in T cells 2Health News:NOW Foods Response to Fish Oil and PCB Concerns 2
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
... The Directigen™ Meningitis Individual Tests ... tests for the direct qualitative ... influenzae type b, S. pneumoniae, ... Escherichia coli K1 in cerebrospinal ...
Medicine Products: